In October of 2010 the FDA approved Pradaxa for the prevention of blood clots and strokes in patients with atrial fibrillation (irregular heartbeat). It was marketed by its manufacturer, Boehringer Ingelheim, as an alternative to warfarin. Over the following year a number of cases of gastrointestinal bleeding were reported, some severe enough to cause death. According to the Cleveland Clinic, Pradaxa had a 33% increased risk of heart attack or heart disease over warfarin.
According to the Institute ...
continue reading...
The Canadian Medical Association (CMA) published an article in its June 2013 medical journal that warns patients of “the use of fluoroquinolones may lead to acute kidney injury.” 
Johnson & Johnson has announced a voluntary recall of millions of oral contraceptive packages, after tests showed that one of the hormones in the pills was being released more slowly than it should.
An investigation by WEWS-TV out of Cleveland uncovered more than 70,000 complaints about the Mirena intrauterine device filed with the U.S. Food and Drug Administration since 2000.
Last week, the U.S. Food and Drug Administration announced a 
